Q1 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Raised by Zacks Research

Surmodics, Inc. (NASDAQ:SRDX) – Equities research analysts at Zacks Research lifted their Q1 2025 earnings estimates for shares of Surmodics in a research report issued to clients and investors on Tuesday, April 9th. Zacks Research analyst D. Dey now forecasts that the company will earn ($0.23) per share for the quarter, up from their previous forecast of ($0.28). The consensus estimate for Surmodics’ current full-year earnings is ($0.90) per share. Zacks Research also issued estimates for Surmodics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at ($0.11) EPS and FY2026 earnings at $0.25 EPS.

Other equities analysts have also recently issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $47.00 price objective on shares of Surmodics in a research report on Wednesday. StockNews.com raised shares of Surmodics from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th.

Surmodics Stock Up 0.1 %

SRDX stock opened at $27.68 on Thursday. The company has a market cap of $394.16 million, a price-to-earnings ratio of 72.84 and a beta of 1.01. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24. Surmodics has a 12 month low of $16.79 and a 12 month high of $39.41. The firm has a 50-day moving average of $30.00 and a two-hundred day moving average of $32.06.

Institutional Investors Weigh In On Surmodics

Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its holdings in Surmodics by 305.8% in the third quarter. Tower Research Capital LLC TRC now owns 775 shares of the company’s stock valued at $25,000 after buying an additional 584 shares in the last quarter. UBS Group AG increased its holdings in Surmodics by 141.1% in the third quarter. UBS Group AG now owns 2,290 shares of the company’s stock valued at $70,000 after buying an additional 1,340 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new position in Surmodics in the third quarter valued at about $87,000. Captrust Financial Advisors increased its holdings in Surmodics by 24.3% in the first quarter. Captrust Financial Advisors now owns 2,307 shares of the company’s stock valued at $105,000 after buying an additional 451 shares in the last quarter. Finally, Citigroup Inc. increased its holdings in Surmodics by 1,023.0% in the second quarter. Citigroup Inc. now owns 4,144 shares of the company’s stock valued at $130,000 after buying an additional 3,775 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).